Humacyte Paradoxically Scales Back As Symvess Begins Its Long Journey
Source: SeekingAlpha
2025-06-09 01:57:15 ET
Introduction
Humacyte's stock ( HUMA ) is down 22% since my Sell rating in March. The company markets Symvess (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma. Notably, Symvess is only indicated in cases where autologous vein graft is not feasible. So, its use is limited to rare cases....
Read the full article on Seeking Alpha
For further details see:
Humacyte Paradoxically Scales Back As Symvess Begins Its Long Journey
Humacyte Inc.
NASDAQ: HUMA
HUMA Trading
0.0% G/L:
$1.165 Last:
1,302,350 Volume:
$1.15 Open:
HUMA Latest News
February 18, 2026 08:00:00 am
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
February 09, 2026 08:00:00 am
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
HUMA Stock Data
$220,166,898
198,988,939
0.6%
62
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
